Liver Cirrhosis Treatment Market Size, Share, Growth Analysis, By Treatment Modality(Antiviral, Vaccines, Chemotherapy, Immunosuppressive Agents), By Disease(Hepatitis, Non-alcoholic Fatty Liver Disease, Alcohol-induced, and Liver Cancer), By Region - Industry Forecast 2025-2032

Liver Cirrhosis Treatment Market size was valued at USD 17.76 Billion in 2023 and is poised to grow from USD 18.9 Billion in 2024 to USD 31.09 Billion by 2032, growing at a CAGR of 6.42% during the forecast period (2025-2032).

Cirrhosis of the liver is a disease characterized by severe liver damage and scarring, leading to liver failure. Major pharmaceutical companies are doing a lot of research to develop new drugs for liver disease. Rapid lifestyle changes increase the risk of liver disease in humans. In addition, people with hepatitis, cystic fibrosis, syphilis, alpha-1 antitrypsin deficiency, alcohol abuse, and other liver diseases are at increased risk of developing cirrhosis of the liver, 887,000 people (about half the population of Idaho) died from hepatitis B. Most of these deaths were from to the fact that these patients had hepatitis B with liver cirrhosis and hepatocellular carcinoma (mainly cancer of the liver).

Key trends likely to drive the growth of the global liver cirrhosis treatment market include population of liver disease, increasing alcohol consumption and poor diet, according to a research study published in Clinical Liver Disease in June 2021. Chronic liver disease affecting about 1.5 billion people worldwide (CLD) is one of the leading causes of death and morbidity worldwide. Moreover, the most common cause of disease is liver non-alcoholic disease (NAFLD) (59%), followed by hepatitis B (2013), according to a June 2021 publication by the American Association for the Study of Liver Diseases. 29%), had hepatitis C (9%), and alcoholic liver disease (ALD) (2%). Furthermore, according to a study published in Clinical and Molecular Hepatology in October 2022, the prevalence of non-alcoholic fatty liver disease (NAFLD) is predicted to be 55.7% by 2040, worldwide therefore liver increasing infections helped to penetrate all markets.